StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the biotechnology company’s stock.
Several other equities analysts have also recently commented on the stock. Barclays lowered their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.00 and set an “underweight” rating on the stock in a research note on Thursday, August 10th. Guggenheim lowered their target price on shares of Adaptimmune Therapeutics from $5.00 to $4.00 in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $4.65.
Adaptimmune Therapeutics Stock Down 10.4 %
Institutional Trading of Adaptimmune Therapeutics
A number of institutional investors have recently added to or reduced their stakes in ADAP. MPM Asset Management LLC acquired a new stake in Adaptimmune Therapeutics in the second quarter valued at approximately $5,816,000. Bank of America Corp DE lifted its stake in Adaptimmune Therapeutics by 357.8% in the fourth quarter. Bank of America Corp DE now owns 4,738,612 shares of the biotechnology company’s stock valued at $6,918,000 after acquiring an additional 3,703,418 shares during the last quarter. Baillie Gifford & Co. lifted its stake in Adaptimmune Therapeutics by 17.1% in the fourth quarter. Baillie Gifford & Co. now owns 17,169,939 shares of the biotechnology company’s stock valued at $25,068,000 after acquiring an additional 2,505,003 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Adaptimmune Therapeutics by 724.5% in the second quarter. Renaissance Technologies LLC now owns 1,506,375 shares of the biotechnology company’s stock valued at $1,393,000 after acquiring an additional 1,323,675 shares during the last quarter. Finally, Artal Group S.A. acquired a new stake in Adaptimmune Therapeutics in the second quarter valued at approximately $1,049,000. 14.55% of the stock is currently owned by institutional investors and hedge funds.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
- Five stocks we like better than Adaptimmune Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- The most upgraded stocks in November have two things in common
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Monday.com rocked earnings like it’s the weekend
- What Is Dividend Yield and How Do You Calculate It?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.